Skip to main content
    V

    Volitionrx Ltd (VNRX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $0.19
    -0.04 (-15.26%)

    Market Cap: $8.30M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Volitionrx Ltd (VNRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Volitionrx reported revenue of $1.73M for the fiscal year ended Dec 31, 2025, up 40.0% from the year before. That year, net income was -$23.50M with a net margin of -1360.6%, operating cash flow was -$19.68M and free cash flow was -$19.77M. The quarter ended Sep 30, 2026 had revenue of $1.61M and net income of -$3.81M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $17.10K, a compound annual rate of 115.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.73M+40.0%100.0%-1258.5%-1360.6%
    Dec 2024$1.23M+59.1%100.0%-2190.9%-2209.8%
    Dec 2023$775.30K+153.0%100.0%-4641.8%-4601.7%
    Dec 2022$306.39K+240.3%100.0%-10372.4%-9986.7%
    Dec 2021$90.03K+235.1%100.0%-31469.0%-29977.0%
    Dec 2020$26.87K+57.1%100.0%-79088.1%-75929.8%
    Dec 2019$17.10KN/A100.0%-93840.2%-186033.0%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.73M$1.23M$775.30K$306.39K$90.03K$26.87K$17.10K$0$0$0
    Gross profit$1.73M$1.23M$775.30K$306.39K$90.03K$26.87K$17.10K$0$0$0
    Research and development$10.08M$14.41M$19.55M$15.33M$13.02M$14.53M$10.36M$10.91M$8.03M$7.90M
    Operating income-$21.74M-$27.02M-$35.99M-$31.78M-$28.33M-$21.25M-$16.04M-$17.90M-$14.70M-$12.43M
    Net income-$23.50M-$27.26M-$35.68M-$30.60M-$26.99M-$20.40M-$31.80M-$18.01M-$14.77M-$11.91M
    EBITDA-$17.84M-$25.59M-$34.14M-$29.36M-$27.16M-$19.28M-$14.79M-$17.26M-$14.17M-$12.12M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.61M$398.66K$985.08K$447.03K$627.28K$406.69K$246.38K$194.59K$474.52K$395.80K$168.60K$243.97K
    Gross profit$1.61M$398.66K$985.08K$447.03K$627.28K$406.69K$246.38K$194.59K$474.52K$395.80K$168.60K$243.97K
    Operating income-$3.33M-$4.16M-$5.35M-$4.82M-$5.10M-$6.30M-$5.52M-$5.78M-$5.87M-$6.99M-$8.38M-$8.74M
    Net income-$3.81M-$7.32M-$6.70M-$6.30M-$5.41M-$6.31M-$5.48M-$5.86M-$5.87M-$7.06M-$8.47M-$8.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $10.57M exceeded cash and equivalents by $9.45M. Shareholder equity was negative, at -$34.25M, as total liabilities of $42.49M exceeded total assets of $6.90M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$6.90M$9.40M$27.95M$18.30M$27.49M$26.15M$21.29M$17.49M$14.62M$24.73M
    Current assets$2.06M$4.06M$21.85M$12.17M$21.98M$20.33M$17.56M$13.90M$10.57M$22.01M
    Cash and equivalents$1.12M$3.26M$20.73M$10.87M$20.58M$19.44M$16.97M$13.43M$10.12M$21.68M
    Total liabilities$42.49M$35.51M$36.66M$21.42M$9.77M$9.86M$7.09M$5.35M$4.67M$3.56M
    Short-term debt$3.31M$860.22K$1.21M$1.07M$797.86K$841.32K$647.57K$416.55K$582.99K$149.67K
    Long-term debt$7.26M$3.95M$3.62M$2.78M$2.27M$2.61M$2.20M$1.98M$1.31M$432.03K
    Shareholder equity-$34.25M-$24.91M-$7.80M-$2.57M$17.72M$16.34M$14.20M$12.14M$9.96M$21.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$7.20M$8.30M$9.04M$6.90M$6.45M$8.70M$8.52M$9.40M$12.68M$13.07M$19.43M$27.95M
    Total liabilities$34.70M$41.84M$42.40M$42.49M$42.40M$41.80M$37.55M$35.51M$35.32M$35.97M$36.05M$36.66M
    Cash and equivalents$2.36M$2.79M$3.10M$1.12M$199.41K$2.26M$2.60M$3.26M$5.41M$6.00M$11.77M$20.73M
    Shareholder equity-$26.12M-$32.16M-$31.97M-$34.25M-$34.64M-$31.82M-$27.77M-$24.91M-$21.50M-$21.81M-$15.61M-$7.80M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$19.68M-$25.89M-$18.06M-$15.28M-$20.85M-$16.46M-$12.74M-$14.73M-$12.19M-$8.86M
    Capital expenditures$89.56K$277.50K$1.08M$1.57M$973.56K$1.94M$511.27K$301.81K$1.43M$415.09K
    Free cash flow-$19.77M-$26.17M-$19.15M-$16.85M-$21.83M-$18.41M-$13.25M-$15.03M-$13.62M-$9.28M
    Dividends paidN/AN/A$1.65M$180.47K$130.43K$346.46KN/AN/AN/AN/A
    Share repurchasesN/AN/A$31.77K$0N/A$54.43K$0N/AN/AN/A
    Investing cash flow-$89.56K-$573.85K-$1.08M-$1.57M-$973.56K-$1.65M-$511.27K-$301.81K-$1.43M-$415.09K
    Financing cash flow$17.09M$8.66M$28.98M$6.94M$22.86M$20.62M$16.93M$17.97M$1.97M$25.19M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.59M-$5.16M-$5.28M-$5.49M-$3.63M-$6.26M-$4.30M-$5.43M-$5.39M-$6.73M-$8.34M$6.45M
    Capital expenditures$46.94K$1.79K$9.21K$10.97K$1.18K$76.78K$1.81K$72.60K$136.74K$39.35K$28.81K$308.72K
    Free cash flow-$4.63M-$5.16M-$5.29M-$5.50M-$3.63M-$6.34M-$4.30M-$5.50M-$5.52M-$6.77M-$8.37M$6.14M
    Last 12 quarters

    Frequently Asked Questions About VNRX

    What is Volitionrx's annual revenue?

    Volitionrx reported revenue of $1.73M for the fiscal year ended Dec 31, 2025.

    How fast is Volitionrx's revenue growing?

    Revenue was up 40.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 78.0%.

    Is Volitionrx profitable?

    No. Volitionrx reported net income of -$23.50M for the fiscal year ended Dec 31, 2025, with a net margin of -1360.6%.

    How much free cash flow does VNRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$19.68M minus capital expenditures of $89.56K produced free cash flow of -$19.77M.

    How much debt does Volitionrx have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $7.26M, short-term debt of $3.31M and cash and equivalents of $1.12M.